tetano
Editor, Senior Moderator
Clin Infect Dis
. 2022 Jun 14;ciac481.
doi: 10.1093/cid/ciac481. Online ahead of print.
Rebound Phenomenon after Nirmatrelvir/Ritonavir Treatment of Coronavirus Disease-2019 in High-Risk Persons
Nischal Ranganath[SUP] 1 [/SUP], John C O'Horo[SUP] 1 2 [/SUP], Douglas W Challener[SUP] 1 [/SUP], Sidna M Tulledge-Scheitel[SUP] 3 [/SUP], Marsha L Pike[SUP] 4 [/SUP], R Michael O'Brien[SUP] 5 [/SUP], Raymund R Razonable[SUP] 1 [/SUP], Aditya Shah[SUP] 1 [/SUP]
Affiliations
Abstract
In a cohort of 483 high-risk patients treated with nirmatrelvir/ritonavir for coronavirus disease-2019, two patients (0.4%) required hospitalization by day 30. Four patients (0.8%) experienced rebound of symptoms, which were generally mild, at median of 9 days after treatment, and all resolved without additional COVID-19-directed therapy.
. 2022 Jun 14;ciac481.
doi: 10.1093/cid/ciac481. Online ahead of print.
Rebound Phenomenon after Nirmatrelvir/Ritonavir Treatment of Coronavirus Disease-2019 in High-Risk Persons
Nischal Ranganath[SUP] 1 [/SUP], John C O'Horo[SUP] 1 2 [/SUP], Douglas W Challener[SUP] 1 [/SUP], Sidna M Tulledge-Scheitel[SUP] 3 [/SUP], Marsha L Pike[SUP] 4 [/SUP], R Michael O'Brien[SUP] 5 [/SUP], Raymund R Razonable[SUP] 1 [/SUP], Aditya Shah[SUP] 1 [/SUP]
Affiliations
- PMID: 35698452
- DOI: 10.1093/cid/ciac481
Abstract
In a cohort of 483 high-risk patients treated with nirmatrelvir/ritonavir for coronavirus disease-2019, two patients (0.4%) required hospitalization by day 30. Four patients (0.8%) experienced rebound of symptoms, which were generally mild, at median of 9 days after treatment, and all resolved without additional COVID-19-directed therapy.